Transcription of EXTERNAL REVIEW – THEOPHYLLINE - WHO archives
{{id}} {{{paragraph}}}
Example: quiz answers
EXTERNAL REVIEW – THEOPHYLLINE - WHO archives
REVIEW THEOPHYLLINE Background The current 13th edition of the WHO Model Essential Medicines List (dated April 2003) includes THEOPHYLLINE as an Essential medicine . The listing is as shown below (together with the other respiratory tract medicines listed). Box 1: 13th Model EML listing of medicines acting on the respiratory tract No indication is given as to whether the tablet formulations listed are immediate-release or of a sustained release form. The entry in the WHO Model Formulary is more extensive, as shown in the box on the next page. It is made clear that the 100mg tablets listed are of the immediate release type, whereas the 200mg and 300mg variants are of a sustained release type. Two important safety messages relevant to the use of methylxanthines are made: Plasma THEOPHYLLINE concentration for optimum response 10 20 mg/litre (55 110 micromol/litre); narrow margin between therapeutic and toxic dose; see notes above; a range of 5 15 mg/litre ( micromol/litre) may be effective and associated with fewer adverse effects , and Patients taking oral THEOPHYLLINE (or aminophylline) should not normally receive intravenous aminophylline unless plasma- THEOPHYLLINE concentration is available to guide dosage.
This review therefore considers the evidence for the possible deletion of theophylline as a specific oral methylxanthine in relation to the listed
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: